Pulmonary Pharmacology (EPUB)
Pulmonary Pharmacology (EPUB)
$276.00 Original price was: $276.00.$28.00Current price is: $28.00.
- The files will be sent to you via E-mail
- Once you placed your order, we will make sure that you receive the files as soon as possible
Pulmonary Pharmacology (EPUB)
1.1.Description
“Pulmonary Pharmacology” offers comprehensive and in-depth reviews of the latest advancements in respiratory drug discovery and development.
This volume presents a wide range of topics, including corticosteroids, monoclonal antibodies, tyrosine kinase inhibitors, and phosphodiesterase inhibitors, focusing on their applications in the treatment of asthma, COPD, and pulmonary fibrosis.
It also explores emerging therapeutic strategies, such as renin-angiotensin system modulators, mitochondrial function modulators, and non-antibacterial macrolides. Additionally, this volume dedicates a section to chemotherapy for lung aging in respiratory diseases and discusses novel pulmonary delivery technologies, including inhaled biologics.
“Pulmonary Pharmacology” provides meticulously reviewed and accurate insights from leading experts in the field of pulmonary pharmacology. Each chapter is designed to facilitate easy comprehension for the audience, incorporating consolidated graphical materials for enhanced readability.
The book not only presents the latest findings in respiratory drug discovery and development but also offers valuable future perspectives. It explores the evolving landscape of drug research and sheds light on potential directions for the treatment of respiratory diseases.
As an EPUB publication, “Pulmonary Pharmacology” ensures accessibility and convenience for readers, allowing them to engage with the content in a digital format. It serves as an authoritative resource for researchers, healthcare professionals, and individuals interested in staying abreast of advancements in the field of pulmonary pharmacology.
1.2.Key Features
I don’t have direct access to specific book content, but based on the context provided, the key features of “Pulmonary Pharmacology” may include:
- Comprehensive Reviews: Offers detailed reviews on respiratory drug discovery and development, covering various medications like corticosteroids, monoclonal antibodies, and kinase inhibitors for treating conditions such as asthma, COPD, and pulmonary fibrosis.
- Cutting-edge Insights: “Pulmonary Pharmacology” Provides the latest advancements and future perspectives in the field of pulmonary pharmacology, including novel therapeutic strategies and delivery technologies for respiratory diseases.
- Expert Contributions: Features contributions from leading experts in the field, ensuring accurate and up-to-date information on drug discovery, development, and treatment modalities for respiratory ailments.
- Graphical Representation: Utilizes consolidated graphical materials in chapters to enhance readability and understanding for a wide audience interested in pulmonary pharmacology.
These features collectively make “Pulmonary Pharmacology” a valuable resource for those involved in respiratory drug research, clinical practice, or academia.
Summary
“Pulmonary Pharmacology” seems to offer comprehensive reviews by leading experts on the latest advancements in respiratory drug discovery and development.
It covers various topics such as corticosteroids, monoclonal antibodies, tyrosine kinase inhibitors, and phosphodiesterase inhibitors for treating conditions like asthma, COPD, and pulmonary fibrosis.
Additionally, the book delves into novel therapeutic strategies like renin-angiotensin system modulators, mitochondrial function modulators, and inhaled biologics, along with discussions on chemotherapy for lung aging in respiratory diseases.
Each chapter consolidates information using graphical materials, providing insights and future perspectives on drug discovery for respiratory conditions.
Respiratory Therapy Exam +20% off |
Essentials of Tuberculosis in Children +20% off |
Principles of Respiratory Medicine, 2nd Edition + 20% off |
Reviews
There are no reviews yet.